Tag Archives: Michael Higgins
Forte Biosciences (FBRX) Gets a Buy Rating from Ladenburg Thalmann & Co.
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Forte Biosciences (FBRX – Research Report), with a price target of $70.00. The company’s shares closed last Tuesday at $49.00. According to TipRanks.com,
Palatin Technologies (PTN) Received its Third Buy in a Row
After H.C. Wainwright and Canaccord Genuity gave Palatin Technologies (NYSE MKT: PTN) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Palatin Technologies today
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Eiger Biopharmaceuticals (EIGR)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $7.96. According to TipRanks.com, Higgins has 0
Analysts Are Bullish on Top Healthcare Stocks: Marinus (MRNS), Moderna (MRNA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Marinus (MRNS – Research Report) and Moderna (MRNA – Research Report) with bullish sentiments. Marinus (MRNS) Ladenburg Thalmann & Co. analyst Michael
Ladenburg Thalmann & Co. Believes Forte Biosciences (NASDAQ: FBRX) Still Has Room to Grow
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Forte Biosciences (FBRX – Research Report), with a price target of $70.00. The company’s shares closed last Thursday at $35.34, close to its
Analysts Have Conflicting Sentiments on These Healthcare Companies: SCYNEXIS (NASDAQ: SCYX) and Esperion (NASDAQ: ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on SCYNEXIS (SCYX – Research Report) and Esperion (ESPR – Research Report). SCYNEXIS (SCYX) Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on
